ERBB2 and breast carcinoma: Chemotherapy followed by endocrine therapy (ET) is the current (neo)adjuvant standard of care for high-risk hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) patients [1].